EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Selenium supplementation in individuals with newly diagnosed Graves’ hyperthyroidism: a double-blind, multi-centre RCT

Per K Cramon, Kristian H Winther, Victor B Boesen, Camilla B Larsen, Jakob B Bjorner, Selma F Nordqvist, Julie L Forman, Anne B Juul, Pernille Bach-Mortensen iD, Nils Knudsen, Runa L Nolsøe, Tina Vilsbøll und 11 weitere

European Thyroid Journal · 2026

DOI: 10.1530/etj-25-0264 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Thyroid Journal, 2026. Verfasst von Per K Cramon und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Selenium, Graves Disease, Dietary Supplements. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

We examined the effect of selenium vs placebo on remission rate and quality of life (QoL) in the Graves’ selenium supplementation (GRASS) trial (ID: NCT01611896).

Methods

Double-blinded, placebo-controlled, multi-centre trial in individuals with newly diagnosed Graves’ hyperthyroidism randomised to daily supplementation with 200 μg selenium or placebo tablets during 24–30 months, depending on the timing of antithyroid drug (ATD) withdrawal. The primary outcome was the proportion of participants with non-remission, defined as receiving ATD or remaining hyperthyroid (thyroid stimulating hormone <0.1 mIU/L) during the last 12 months of the intervention period or referral to ablative therapy (radioactive iodine or surgery). QoL was serially assessed by the thyroid-related patient-reported outcome ThyPRO and compared with previously collected norm data.

Results

Between Dec 7th 2012 and Dec 3rd 2018, 430 participants with Graves’ hyperthyroidism were recruited. Non-remission was observed in 114 (53.3%) participants in the placebo group and 118 (54.6%) in the selenium group (OR = 1.0 (95% CI: 0.7–1.5); P = 0.98). There was no beneficial effect of selenium, as compared with placebo, on any ThyPRO scale. The participants’ QoL at the end of the study was comparable to that of the general population sample. Thyrotropin receptor antibody levels were similar in the groups at the 18-month and end-of-study follow-up visits.

Conclusion

In individuals with newly diagnosed Graves’ hyperthyroidism, daily supplementation with selenium did not have any effects compared with placebo as add-on to standard antithyroid drugs. The GRASS trial findings do not support the use of selenium supplementation in Graves’ hyperthyroidism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SeleniumGraves DiseaseDietary SupplementsHumansDouble-Blind MethodFemaleMaleAdultMiddle AgedQuality of LifeAntithyroid AgentsTreatment Outcome

Stichwörter der Autor:innen

Graves’ diseaseGraves’ hyperthyroidismThyPROpragmatic trialquality of lifeselenium

Substanzen

SeleniumAntithyroid Agents

Autor:innen und Institutionen

  • Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Department of Endocrinology, Odense University Hospital, Odense, Denmark.
  • Department of Nephrology and Endocrinology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • IQVIA, Copenhagen, Denmark.
  • Department of Public Health, Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark.
  • Department of Endocrinology, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark.

ORCID-Profile: Pernille Bach-Mortensen, Birte Nygaard, Åse K Rasmussen

Zitieren

APA

Cramon, P. K., Winther, K. H., Boesen, V. B., Larsen, C. B., Bjorner, J. B., Nordqvist, S. F., Forman, J. L., Juul, A. B., Bach-Mortensen, P., Knudsen, N., Nolsøe, R. L., Vilsbøll, T., Andries, A., Gram, J., Nygaard, B., Demircan, K., Chillon, T. S., Schomburg, L., Hegedüs, L., …, & Watt, T. (2026). Selenium supplementation in individuals with newly diagnosed Graves’ hyperthyroidism: a double-blind, multi-centre RCT. European Thyroid Journal. https://doi.org/10.1530/etj-25-0264

Vancouver

Cramon PK, Winther KH, Boesen VB, Larsen CB, Bjorner JB, Nordqvist SF, et al. Selenium supplementation in individuals with newly diagnosed Graves’ hyperthyroidism: a double-blind, multi-centre RCT. European Thyroid Journal. 2026. doi:10.1530/etj-25-0264

BibTeX
@article{Cramon2026,
  author = {Cramon, Per K and Winther, Kristian H and Boesen, Victor B and Larsen, Camilla B and Bjorner, Jakob B and Nordqvist, Selma F and Forman, Julie L and Juul, Anne B and Bach-Mortensen, Pernille and Knudsen, Nils and Nolsøe, Runa L and Vilsbøll, Tina and Andries, Alin and Gram, Jeppe and Nygaard, Birte and Demircan, Kamil and Chillon, Thilo S and Schomburg, Lutz and Hegedüs, Laszlo and Bonnema, Steen J and Feldt-Rasmussen, Ulla and Rasmussen, Åse K and Watt, Torquil},
  title = {Selenium supplementation in individuals with newly diagnosed Graves’ hyperthyroidism: a double-blind, multi-centre RCT},
  journal = {European Thyroid Journal},
  year = {2026},
  doi = {10.1530/etj-25-0264}
}
Kostenlos starten →